Literature DB >> 21102530

Medical oncology: Chemoradiotherapy for NSCLC-does a 'standard' exist?

Allen M Chen, Primo N Lara.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 21102530     DOI： 10.1038/nrclinonc.2010.191

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  7 in total

1.  Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105.

Authors:  Nobuyuki Yamamoto; Kazuhiko Nakagawa; Yasumasa Nishimura; Kayoko Tsujino; Miyako Satouchi; Shinzoh Kudo; Toyoaki Hida; Masaaki Kawahara; Koji Takeda; Nobuyuki Katakami; Toshiyuki Sawa; Soichiro Yokota; Takashi Seto; Fumio Imamura; Hideo Saka; Yasuo Iwamoto; Hiroshi Semba; Yasutaka Chiba; Hisao Uejima; Masahiro Fukuoka
Journal:  J Clin Oncol       Date:  2010-07-12       Impact factor: 44.544

2.  Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol.

Authors:  Chandra P Belani; Hak Choy; Phil Bonomi; Charles Scott; Patrick Travis; John Haluschak; Walter J Curran
Journal:  J Clin Oncol       Date:  2005-08-08       Impact factor: 44.544

Review 3.  Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer.

Authors:  Anne Aupérin; Cecile Le Péchoux; Estelle Rolland; Walter J Curran; Kiyoyuki Furuse; Pierre Fournel; Jose Belderbos; Gerald Clamon; Hakki Cuneyt Ulutin; Rebecca Paulus; Takeharu Yamanaka; Marie-Cecile Bozonnat; Apollonia Uitterhoeve; Xiaofei Wang; Lesley Stewart; Rodrigo Arriagada; Sarah Burdett; Jean-Pierre Pignon
Journal:  J Clin Oncol       Date:  2010-03-29       Impact factor: 44.544

4.  Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.

Authors:  K Furuse; M Fukuoka; M Kawahara; H Nishikawa; Y Takada; S Kudoh; N Katagami; Y Ariyoshi
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

5.  Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504.

Authors:  David R Gandara; Kari Chansky; Kathy S Albain; Bryan R Leigh; Laurie E Gaspar; Primo N Lara; Howard Burris; Paul Gumerlock; J Philip Kuebler; James D Bearden; John Crowley; Robert Livingston
Journal:  J Clin Oncol       Date:  2003-05-15       Impact factor: 44.544

Review 6.  Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation.

Authors:  Nuran Senel Bese; Jolyon Hendry; Branislav Jeremic
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-04-30       Impact factor: 7.038

7.  Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology.

Authors:  Nasser Hanna; Marcus Neubauer; Constantin Yiannoutsos; Ronald McGarry; James Arseneau; Rafat Ansari; Craig Reynolds; Ramaswamy Govindan; Anton Melnyk; William Fisher; Donald Richards; Daniel Bruetman; Thomas Anderson; Naveed Chowhan; Sreenivasa Nattam; Prasad Mantravadi; Cynthia Johnson; Tim Breen; Angela White; Lawrence Einhorn
Journal:  J Clin Oncol       Date:  2008-11-10       Impact factor: 44.544
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.